SCHEMBL284551

SCHEMBL284551

CC(C)c1cc(N)n(CC2CCCC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PKM P14618 1/20 0.40
LMNA P02545 1/20 0.37
HTR2C P28335 7/20 0.37
SLC6A4 P31645 7/20 0.37
HTR2A P28223 5/20 0.37
CNR1 P21554 2/20 0.36
CNR2 P34972 2/20 0.34
ACHE P22303 1/20 0.34
P2RY14 Q15391 2/20 0.34
MERTK Q12866 1/20 0.34
GRM2 Q14416 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
MTOR P42345 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16168602 0.80 MAPT (0.43) MAPTMEN1RAB9AKMT2ANPSR1
SCHEMBL12440140 0.80 MAPT (0.43) MAPTMEN1RAB9AKMT2ANPSR1
SCHEMBL282886 0.78 MEN1 (0.44) MAPTMEN1RAB9AKMT2ANPSR1
SCHEMBL27821986 0.75 RAB9A (0.42) MAPTMEN1RAB9AKMT2ANPSR1
SCHEMBL281636 0.74 MAPT (0.41) MAPTMEN1RAB9AKMT2ANPSR1
SCHEMBL23566807 0.74 CRHR1 (0.43) MAPTMEN1RAB9AKMT2ANPSR1
SCHEMBL18692292 0.72 HPGD (0.41) MAPTRAB9APIK3CDPIK3CAPIK3CB
SCHEMBL17045358 0.72 ADORA2A (0.39) MEN1KMT2APIK3CDPRKDC
SCHEMBL22667106 0.72 CRHR1 (0.50) MAPTMEN1RAB9AKMT2ANPSR1
SCHEMBL284527 0.72 HTR2C (0.33) MAPTMEN1RAB9AKMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2428507-B1 Cannabinoid receptor ligands ABBVIE BAHAMAS LTD (BS) 2015-10-21 EP disclosed
EP-2896615-A1 Cannabinoid receptor ligands AbbVie Bahamas Limited (BS) 2015-07-22 EP disclosed
US-8859596-B2 Compounds as cannabinoid receptor ligands ABBVIE INC. (US) 2014-10-14 US disclosed
US-8188135-B2 Compounds as cannabinoid receptor ligands ABBOTT LABORATORIES (US) 2012-05-29 US disclosed
EP-2428507-A2 Cannabinoid receptor ligands Abbott Laboratories (US) 2012-03-14 EP disclosed
CN-102216277-A Substituted benzamides as cannabinoid receptor ligands ABBOTT LAB 2011-10-12 CN disclosed
US-20100069348-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
US-20100069349-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069348-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, NPY1R MAPT 3688/4885MEN1 2912/4885RAB9A 915/4885
US-20100069349-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, NPY1R MAPT 3688/4885MEN1 2912/4885RAB9A 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.